Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • ThePresident
    Member
    • Jun 2012
    • 72

    #1

    Understanding VCF output from mpileup

    Hello,

    As a start, I would like to mention that I just passed 2 hours reading older threads here and on biostar as well as the VCF specification sheet.

    That been said, I have a question upon calling a SNPs from RNA-seq data (Illumina signle-read, bacterial) with mpileup. I got my VCF file and I'm struggling a little bit to understand the output. If I have:

    Code:
    gi|xxx|emb|xxx|	143630	.	C	T	999	.	DP=490	VDB=0.0004	AF1=1	AC1=4	DP4=1,0,211,276	MQ=20	FQ=-286	PV4=0.43,1.5e-11,1,0.048		GT:PL:GQ	1/1:255,255,0:99	1/1:255,255,0:99
    I'm pretty sure of the following:
    1. 143630 is the position of my SNPs
    2. C is the base in the reference genome and T the alternate variant (actual SNPs)
    3. 999 is the score. The higher it is, better the chances that the call is genuine
    4. DP is the actual coverage on that specific position
    5. DP4 are reads fwd and rev for reference and fwd and rev for alternate call
    6. MQ is the quality


    Now, here are my questions:
    1. VDB is supposed to be Variant Distance Bias. What exaclt does it means and how I interpret it?
    2. AF1 is Allele Frequency. By 1 it means that all the reads are calling the SNPs? If I have AF1=0.5, it means that half of the reads are calling ref nucleotide while the other half is calling SNP?
    3. What the heck is AC1? Max likelihood okay, but how you interpret it?
    4. How do you interpret FQ (Phred probability), i.e. lower vs higher?
    5. PV4 is a total mess... Any insight would be greatly appreciated.
    6. GT:PL:GQ: same as above.


    I know that this is probably very basic for most of you, but I'm just trying to make some sense out of it...

    Thank you all in advance,

    TP

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 08-13-2026, 12:22 PM
0 responses
29 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-11-2026, 10:35 AM
0 responses
24 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
38 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-03-2026, 10:13 AM
0 responses
51 views
0 reactions
Last Post SEQadmin2  
Working...